All In Biotech

Drug Trial Radar · NCT00701363

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

A Prospective, International, Multi-centric, Open-label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on the Long Term Treatment With Octreotide LAR 10 or 20 mg

Last checked: Nov 20, 2026Latest source record: Jan 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

124

Actual

Start

Oct 2008

Primary completion

Mar 2013

Study completion May 2013

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Jun 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the efficacy of an extended injection interval schedule of lanreotide Autogel 120 mg in acromegalic subjects who are biochemically controlled on long term treatment with octreotide LAR 10 or 20 mg

Conditions

  • Acromegaly

Interventions

  • Lanreotide Autogel 120 mgDrug

    120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Having Maintained Their Injection Interval Schedule of Six Weeks or Increased Their Injection Interval to Eight Weeks Whilst Keeping Their Normalised Insulin Growth Factor (IGF-1) Levels (Age and Sex Adjusted)Time frame: At week 48 (End of Study)

Locations

44 sites in 14 countries. Site status is shown where the registry gives one.

  • Universidade Federal do Rio de Janeiro - Department of Internal Medicine - Section of Endocrinology - Neuroendocrine Research Center

    Rio de Janeiro, Brazil

  • Hospital das Clínicas de São Paulo - Internal Medicine - Neuroendocrine Unit - Division of Endocrinology and Metabolism

    São Paulo, Brazil

  • Arhus University Hospital - Department of Medicinsk AVd M

    Arhus C, Denmark

  • Righospitalet - University Department of Endocrinology & Internal Medicine P

    Copenhagen, Denmark

  • Odense University Hospital - Department of Endocrinology

    Odense C, Denmark

  • Helsinki University Central Hospital - (HUCH) Division of Endocrinology - Department of Medicine

    Helsinki, Finland

  • Kuopio University Hospital - Department of Medicine, Internal Medicine/Endocrinology and Diabetology Division

    Kuopio, Finland

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, France

  • Hôpital Avicenne - Bâtiment Madeleine Breis

    Bobigny, France

  • Hôpital Neurologique - Pierre Wertheimer

    Bron, France

  • Hôpital du Bocage Sud - Service d'Endocrinologie

    Dijon, France

  • CH La Rochelle - Hopital Saint Louis - Service de Médecine interne - Endocrinologie - Maladies Métaboliques- Nutrition

    La Rochelle, France

  • Hôpital Du Cluzeau - Service de Médecine B

    Limoges, France

  • Hôpital Archet 1 - Service d'Endocrinologie

    Nice, France

  • CHU de Nîmes - Hôpital Caremeau

    Nîmes, France

  • Hôpital Lariboisière - Service Médecine Interne - Endocrinologie - Nutrition

    Paris, France

  • Hopital Pitié-Salpêtrière - Service d'Endocrinologie

    Paris, France

  • Hôpital Cochin - Saint-Vincent-de-Paul - La-Roche-Guyon

    Paris, France

  • Hôpital Haut Lévêque - Unité de soins normalisés

    Pessac, France

  • Hôpital Robert Debré

    Reims, France

  • Hôpital de Hautepierre, Service de Médecine Interne et Nutrition

    Strasbourg, France

  • CHU de Tours - Hopital Bretonneau - Service Endocrinologie-Diabétologie Medecine B

    Tours, France

  • Evangelismos Hospital - Department of Endocrinology

    Athens, Greece

  • Polykliniki Hospital - Department of Endocrinology

    Athens, Greece

  • Metaxa Hospital - Department of Endocrinology

    Piraeus, Greece

  • B IKA Panagia Hospital - Department of Endocrinology

    Thessaloniki, Greece

  • P. Stradins Clinical University Hospital - Department of Endocrinology

    Riga, Latvia

  • Erasmus Medical Centre - Department of Endocrinology

    Rotterdam, Netherlands

  • UMC Utrecht - Department of Endocrinology, Heidelberglaan 100

    Utrecht, Netherlands

  • Department of Medicine, Haukeland Hospital Jonas Lies

    Bergen, Norway

  • Swietorkryskie Centrum Onkologii, UL. Artwinskiego 3 - Department of endocrinology and Nuclear Medecine

    Kielce, Poland

  • University Hospital in Krakow, Dept. of Endocrinology, Kopernika Str. 17

    Krakow, Poland

  • Samodzielny Publiczny Szpital Kliniczny nr 1, Ul. Pasteura 4

    Wroclaw, Poland

  • University of Medicine and Pharmacy Iuliu Hatieganu

    Cluj-Napoca, Romania

  • Federal State Institution "Endocrinology Research Centre - Federal agency of high-tech medical care" - Neuroendocrinology & Osteopathy Department

    Moscow, Russia

  • I.M. Sechenov Moscow Medical Academy - Endocrinology Department

    Moscow, Russia

  • Clinical Centre of Serbia - Institute for Endocrinology, Diabetes and Metabolic Diseases, - Dr Subotica Street n°13

    Belgrade, Serbia

  • Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Hajduk Veljkova 3-9

    Novi Sad, Serbia

  • Seoul National University hospital, 28 Yongon-dong Chongno-gu

    Seoul, South Korea

  • Yonsei University Severance Hospital - Department of Endocrinology and Metabolism

    Seoul, South Korea

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.